GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jiangsu Bioperfectus Technologies Co 688399.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

22.72

-2.11%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jiangsu Bioperfectus Technologies Co

Its shares trade on Shanghai under the ticker 688399.SS. It has been listed since 5 December 2019. In the fiscal year to 31 December 2025, it reported revenue of CN¥340.4m and a net loss of CN¥39.7m. At that date it held total assets of CN¥3.55bn and shareholders' equity of CN¥2.93bn.

Jiangsu Bioperfectus Technologies Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents and supporting testing instruments. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2019-12-05. The firm's products mainly include in vitro diagnostic reagents, supporting testing instruments and in vitro testing services. Its products are mainly used in the fields of infectious disease prevention and control, clinical testing, large-scale population screening, as well as prenatal and postnatal care management. The firm mainly conducts its businesses in domestic and overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
5 Dec 2019
Employees
1,082

Leadership

Pay as last reported

  • Mr. Yongsheng FangChairman of the Board, since 2011CN¥11.9m
  • Mr. Guoqiang WangVice Chairman of the Board, General Manager, since 2010CN¥16.9m
  • Ms. Yuanyuan MengChief Financial Officer
  • Mr. Zhonghua LiuChief Technology Officer, Deputy General Manager, Director, since 2010CN¥9.0m
  • Ms. Yuanyuan HuDeputy General Manager, Secretary of the Board, Director, since 2022
  • Mr. Lei PeiDeputy General Manager
  • Mr. Guohui ZhouDeputy General Manager
  • Mr. Haitao GuoDirector
  • Mr. Bocheng LiangDirector
  • Mr. Guangxia GaoIndependent Director
  • Mr. Xiaolun LiuIndependent Director
  • Mr. Shunhai YangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company employs 1082 full-time employees.
  • Products include in vitro diagnostic reagents and supporting testing instruments.
  • Operates in both domestic and overseas markets.

Weaknesses

  • No specific weaknesses mentioned in the provided information.
  • No details on financial performance or market share provided.
  • No information on competitive advantages or unique technologies.

Opportunities

  • Growing demand for in vitro diagnostic reagents in infectious disease prevention.
  • Expansion into large-scale population screening markets.
  • Potential for increased international market presence.

Threats

  • No specific threats mentioned in the provided information.
  • No details on regulatory challenges or market competition.
  • No information on economic or geopolitical risks affecting operations.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.